Understanding How Inflammasome Activity Affects Chemotherapy Response in Adults with Acute Myeloid Leukemia

What this Trial Is About

Researchers are studying acute myeloid leukemia AML, a fast-growing cancer mainly affecting bone marrow cells, especially in older adults. This study focuses on how the inflammasome, a part of the immune system that controls inflammation, affects AML development and the response to chemotherapy. Understanding this connection may help explain why some patients respond differently to treatment and could guide the creation of personalized therapies. Patients with newly diagnosed AML will have biological samples, including peripheral blood and bone marrow, collected and analyzed before and after their first-line chemotherapy. The study includes both prospective and retrospective parts, with patients undergoing standard treatments following clinical guidelines. Common chemotherapy regimens include intensive protocols like 37 with daunorubicin and cytarabine, sometimes combined with other drugs, and non-intensive treatments such as azacitidine with venetoclax. During the study, participants will follow their usual diagnostic and treatment plans while additional blood and bone marrow samples are collected for research purposes. Researchers will perform tests like inflammasome activity assays, gene expression analysis, and immunophenotyping to evaluate treatment response and disease progression. The main outcome is to measure inflammasome activity at diagnosis, in case of treatment failure, and six months after starting chemotherapy. The observation period lasts up to six months, with data collected to monitor disease status and treatment effects.

Decoding the Inflammasome Influence on Treatment Response in Acute Myeloid Leukemia